Health Catalyst, Inc. (NASDAQ:HCAT) Receives $9.27 Average PT from Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven analysts that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.27.

A number of research firms recently commented on HCAT. Piper Sandler cut their target price on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Canaccord Genuity Group lowered their price target on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 21st. Royal Bank of Canada dropped their price target on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 27th. Stephens reduced their price objective on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Finally, KeyCorp raised Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th.

Health Catalyst Price Performance

HCAT stock traded up $0.12 during trading on Friday, hitting $4.45. The company had a trading volume of 441,111 shares, compared to its average volume of 614,976. The business has a 50 day moving average of $4.96 and a 200 day moving average of $6.78. The firm has a market capitalization of $312.44 million, a price-to-earnings ratio of -3.30 and a beta of 1.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a fifty-two week low of $3.76 and a fifty-two week high of $9.24.

Remove Ads

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the sale, the chief operating officer now owns 91,253 shares of the company's stock, valued at $685,310.03. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the transaction, the insider now directly owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,530 shares of company stock valued at $299,572 in the last quarter. Insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Light Asset Management LLC grew its position in Health Catalyst by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock worth $37,055,000 after buying an additional 944,631 shares in the last quarter. Impax Asset Management Group plc increased its position in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after purchasing an additional 195,525 shares during the period. Daventry Group LP raised its stake in shares of Health Catalyst by 3.8% in the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock valued at $17,742,000 after purchasing an additional 91,878 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock worth $14,277,000 after purchasing an additional 861,150 shares during the period. Finally, Kennedy Capital Management LLC boosted its stake in Health Catalyst by 42.7% during the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company's stock worth $13,369,000 after buying an additional 565,445 shares in the last quarter. Institutional investors own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.